Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
News|Articles|June 9, 2026
Melanoma Trials You May Have Missed at ASCO 2026
Author(s)Cancer Network Staff
Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
The
Related to this article
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in the lung cancer field.
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
Advertisement
Advertisement